These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 29580635)

  • 61. ACP Journal Club. Review: non-calcium-based phosphate binders reduce mortality compared with calcium-based binders in CKD.
    Parikh CR
    Ann Intern Med; 2013 Nov; 159(10):JC2. PubMed ID: 24247692
    [No Abstract]   [Full Text] [Related]  

  • 62. Most consumed processed foods by patients on hemodialysis: Alert for phosphate-containing additives and the phosphate-to-protein ratio.
    Watanabe MT; Araujo RM; Vogt BP; Barretti P; Caramori JCT
    Clin Nutr ESPEN; 2016 Aug; 14():37-41. PubMed ID: 28531397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.
    Aleidi AM; Alayed NJ; Alduraibi HM; Alqassimi NS; Ismail AA
    Saudi Med J; 2020 Oct; 41(10):1076-1082. PubMed ID: 33026048
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned.
    Zoccali C; Mallamaci F
    Nephrol Dial Transplant; 2016 Feb; 31(2):196-9. PubMed ID: 26681749
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum phosphorus in people with chronic kidney disease: you are what you eat.
    Tonelli M
    Kidney Int; 2013 Nov; 84(5):871-3. PubMed ID: 24172733
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Modelling of phosphorus transfers during haemodialysis].
    Chazot G; Lemoine S; Juillard L
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S89-S93. PubMed ID: 28577749
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treating hyperphosphatemia - current and advancing drugs.
    Ketteler M; Liangos O; Biggar PH
    Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel iron-based phosphate binders in patients with chronic kidney disease.
    Shah HH; Hazzan AD; Fishbane S
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dietary phosphorus, serum phosphorus, and cardiovascular disease.
    Menon MC; Ix JH
    Ann N Y Acad Sci; 2013 Oct; 1301():21-6. PubMed ID: 24117725
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Management of phosphate abnormalities in hemodialysis patients: Findings from Malaysia.
    Mohamed Koya SNM
    Saudi J Kidney Dis Transpl; 2019; 30(3):670-677. PubMed ID: 31249232
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions.
    Humalda JK; Keyzer CA; Binnenmars SH; Kwakernaak AJ; Slagman MC; Laverman GD; Bakker SJ; de Borst MH; Navis GJ
    Nutr Metab Cardiovasc Dis; 2016 Aug; 26(8):689-96. PubMed ID: 27266988
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reexamining the Phosphorus-Protein Dilemma: Does Phosphorus Restriction Compromise Protein Status?
    St-Jules DE; Woolf K; Pompeii ML; Kalantar-Zadeh K; Sevick MA
    J Ren Nutr; 2016 May; 26(3):136-40. PubMed ID: 26873260
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Chronic kidney disease--mineral and bone disorder: why and how to control phosphate].
    Pavlović D; Katicić D; Josipović J
    Acta Med Croatica; 2012 Oct; 66 Suppl 2():64-7. PubMed ID: 23513419
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients.
    Tsai WC; Yang JY; Luan CC; Wang YJ; Lai YC; Liu LC; Peng YS
    Clin Exp Nephrol; 2016 Oct; 20(5):815-821. PubMed ID: 26658792
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The demise of calcium-based phosphate binders.
    Ortiz A; Sanchez-Niño MD
    Lancet; 2013 Oct; 382(9900):1232-4. PubMed ID: 23870814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.